. 2004 Jul 23;101(31):11432–11437. doi: 10.1073/pnas.0403969101

Table 1. Effect of SEMA3B-CM and VEGF isoforms 165 and 121 on proliferation in H1299 lung and MDA-MB-231 breast cancer cells.

Treatment^*	H1299 Cell no. (× 10⁻⁴) (P value)^†	MDA-MB-231 Cell no. (× 10⁻⁴) (P value)^†
Control-CM^‡	11 ± 1.3 (−)	16 ± 1.0 (−)
SEMA3B-CM^‡	6 ± 0.6 (0.002)^§	5 ± 2.0 (0.002)^§
SEMA3Bmut1-CM^¶	11 ± 1.0 (0.0005)^∥	15 ± 0.5 (0.0005)^∥
SEMA3B-CM plus anti-SEMA3B^**	11 ± 1.5 (0.004)^∥	13 ± 1.0 (0.004)^∥
VEGF₁₂₁	11 ± 0.8 (NS)^††	16 ± 1.0 (NS)^††
VEGF₁₆₅	11 ± 0.8 (NS)^††	16 ± 2.0 (NS)^††
VEGF₁₂₁ plus SEMA3B-CM	6 ± 1.2 (0.004)^‡‡	8 ± 0.3 (0.003)^‡‡
VEGF₁₆₅ plus SEMA3B-CM	12 ± 1.5 (0.0002)^∥	15 ± 0.6 (0.003)^∥
VEGF₁₆₅ plus anti-VEGF-A Ab	12 ± 0.9 (NS)^§§	14 ± 0.8 (NS)^§§
VEGF₁₆₅ plus SEMA3B-CM plus anti-VEGF Ab^**	7 ± 0.6 (0.001)^¶¶	4 ± 0.9 (0.001)^¶¶

CM from cells transfected with various plasmids as specified above was added to MDA-MB-231 and H1299 cells.

^†

P value was calculated by using a two-tailed Student's t test.

^‡

Cos7 cells were transfected with vector control or with SEMA3B expression vector, and CM was collected 48 h thereafter.

^§

Significant decrease as compared with Control-CM.

^¶

SEMA3B-mut-CM (D397H) is inactive as described in Materials and Methods and Results.

^∥

Significant increase as compared with SEMA3B-CM.

^**

Anti-SEMA3B or anti-VEGF (30 μg/ml) antibody 2C3 was used as neutralizing agent for SEMA3B-CM and VEGF₁₆₅, respectively.

^††

Nonsignificant as compared with control.

^‡‡

Significant decrease when compared with cells treated with VEGF₁₂₁.

^§§

Nonsignificant as compared with VEGF₁₆₅.

^¶¶

Significant decrease as compared with VEGF₁₆₅ plus SEMA3B-CM.